Real-time Estimate Cboe BZX  -  05/23 02:55:04 pm EDT
72.68 USD   +2.18%
05/19Morgan Stanley Adjusts Price Target for Sarepta Therapeutics to $74 From $77, Maintains Equalweight Rating
05/11TRANSCRIPT : Sarepta Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 09:20 AM
05/05RBC Capital Adjusts Sarepta Therapeutics Price Target to $155 From $150, Maintains Outperform Rating
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sarepta Therapeutics : Announces Recipients of Route 79, The Duchenne Scholarship Program

09/15/2020 | 08:31am EDT

CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 21 recipients of Route 79, The Duchenne Scholarship Program. This is the third year of the scholarship program, which was created to recognize exceptional individuals with Duchenne muscular dystrophy as they pursue their post-secondary education. Recipients were chosen by an independent selection committee composed of Duchenne community members, who consider each applicant’s community involvement and a personal essay. Each student will receive a scholarship of up to $5,000.

“It is our great privilege to announce and congratulate the 2020 recipients of Route 79, The Duchenne Scholarship Program. With each new class of applicants, we are reminded of the varied interests, skills, and goals of these bright young people. Their perseverance and resiliency, particularly in the face of the challenges and uncertainties brought on by COVID, set a powerful example for others living with Duchenne,” said Diane Berry, Sarepta’s Senior Vice President of Global Health Policy, Government and Patient Affairs. “It is an honor to play a role in supporting their journey in higher education and we wish them great success. Additionally, I want to extend gratitude and appreciation to the selection committee for generously giving of their time to review the applications and essays.”

2020 Named Recipients - Route 79, The Duchenne Scholarship Program

Praise Akintola, Farmingdale State College

Porter Aydelotte, Saddleback College

Donovan Carlson, University of Illinois at Urbana-Champaign

Tyler Cooley, Arizona State University

Lucas Currier, Great Bay Community College

Benjamin Dupree, The University of Texas at Arlington

Cole Dutton, West Texas A&M University

Aiden Fecteau, Eastern Connecticut State University

Yuvaraj Gambhir, University of Pennsylvania

Justin Gibbons, Saint Bonaventure University

William Hancock, Merrimack College

Joshua Jurack, James Madison University

Brian Le, Stanford University

Brian Madura, New Jersey Institute of Technology

Alice McConnell, University of Idaho

Nicholas O'Neill, Morrisville State College

Spencer Poole, Saint Joseph’s College - Suffolk Campus

Jordan Reidenberg, University of Delaware

Nathan Rothe, Texas Christian University

Christian Tumminello, Pennsylvania College of Technology

Jack Willis, Syracuse University

Scholarship recipients are chosen by an independent committee of Duchenne community members based on each applicant’s essay and demonstrated level of community involvement. Submissions are de-identified for the voting panel with no indication of whether the candidate has received, or plans to receive, a Sarepta therapy.

About Route 79, The Duchenne Scholarship Program

Route 79, The Duchenne Scholarship Program is designed to help students diagnosed with Duchenne muscular dystrophy (Duchenne) pursue their post-high school educational goals. There are 79 exons in the dystrophin gene impacted by Duchenne, and the route traveled by every person with Duchenne is distinct. Sarepta’s goal through this program is to acknowledge and support individuals with Duchenne who are mapping out their future via educational pursuits. Additional information is available at

About Sarepta Therapeutics
At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visit or follow us on TwitterLinkedInInstagram and Facebook.

Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Investors: Ian Estepan, 617-274-4052,

Media: Tracy Sorrentino, 617-301-8566,

Sarepta- Corporate Logo (Image).jpg

Source: Sarepta Therapeutics, Inc.

2020 GlobeNewswire, Inc., source Press Releases

05/19Morgan Stanley Adjusts Price Target for Sarepta Therapeutics to $74 From $77, Maintains..
05/11TRANSCRIPT : Sarepta Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Confer..
05/05RBC Capital Adjusts Sarepta Therapeutics Price Target to $155 From $150, Maintains Outp..
05/04Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 Loss $-0.56
05/04Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 Loss $-0.56
05/04Earnings Flash (SRPT) SAREPTA THERAPEUTICS Reports Q1 Revenue $210.8M, vs. Street Est o..
05/04TRANSCRIPT : Sarepta Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022
05/04SAREPTA THERAPEUTICS : Q1 Earnings Snapshot
05/04SAREPTA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
05/04Sarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporat..
More news
Analyst Recommendations on SAREPTA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 900 M - -
Net income 2022 -385 M - -
Net cash 2022 626 M - -
P/E ratio 2022 -16,1x
Yield 2022 -
Capitalization 6 224 M 6 224 M -
EV / Sales 2022 6,22x
EV / Sales 2023 5,41x
Nbr of Employees 840
Free-Float 95,7%
Duration : Period :
Sarepta Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAREPTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 21
Last Close Price 71,13 $
Average target price 119,40 $
Spread / Average Target 67,9%
EPS Revisions
Managers and Directors
Douglas S. Ingram President, Chief Executive Officer & Director
Ian M. Estepan Executive VP, Chief Financial & Accounting Officer
M. Kathleen Behrens Wilsey Chairman
Louise Rodino-Klapac Chief Scientific Officer & Executive VP
Hans Lennart Rudolf Wigzell Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-12.08%80 075
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612